The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis
Jayne E Murray,Emanuele Valli,Giorgio Milazzo,Chelsea Mayoh,Andrew J Gifford,Jamie I Fletcher,Chengyuan Xue,Nisitha Jayatilleke,Firoozeh Salehzadeh,Laura D Gamble,Jourdin R C Rouaen,Daniel R Carter,Helen Forgham,Eric O Sekyere,Joanna Keating,Georgina Eden,Sophie Allan,Stephanie Alfred,Frances K Kusuma,Ashleigh Clark,Hannah Webber,Amanda J Russell,Antoine de Weck,Benjamin T Kile,Martina Santulli,Piergiuseppe De Rosa,Emmy D G Fleuren,Weiman Gao,Lorna Wilkinson-White,Jason K K Low,Joel P Mackay,Glenn M Marshall,Douglas J Hilton,Federico M Giorgi,Jan Koster,Giovanni Perini,Michelle Haber,Murray D Norris
DOI: https://doi.org/10.1038/s41467-024-49871-0
2024-07-11
Abstract:MYCN oncogene amplification is frequently observed in aggressive childhood neuroblastoma. Using an unbiased large-scale mutagenesis screen in neuroblastoma-prone transgenic mice, we identify a single germline point mutation in the transcriptional corepressor Runx1t1, which abolishes MYCN-driven tumorigenesis. This loss-of-function mutation disrupts a highly conserved zinc finger domain within Runx1t1. Deletion of one Runx1t1 allele in an independent Runx1t1 knockout mouse model is also sufficient to prevent MYCN-driven neuroblastoma development, and reverse ganglia hyperplasia, a known pre-requisite for tumorigenesis. Silencing RUNX1T1 in human neuroblastoma cells decreases colony formation in vitro, and inhibits tumor growth in vivo. Moreover, RUNX1T1 knockdown inhibits the viability of PAX3-FOXO1 fusion-driven rhabdomyosarcoma and MYC-driven small cell lung cancer cells. Despite the role of Runx1t1 in MYCN-driven tumorigenesis neither gene directly regulates the other. We show RUNX1T1 forms part of a transcriptional LSD1-CoREST3-HDAC repressive complex recruited by HAND2 to enhancer regions to regulate chromatin accessibility and cell-fate pathway genes.